Meningitis Diagnostic Testing Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Meningitis Diagnostic Testing Market Size, Share & Trends Analysis Report By Infection Type, Diagnosis Type, By End-user, By Region, And Segment Forecasts, 2024 – 2031

Market Overview

Global Meningitis Diagnostic Testing Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031

Meningitis is an infection and inflammation of the meninges, the fluid and membranes surrounding the brain and spinal cord. Symptoms include headache, fever, and stiff neck. Most cases in the US are caused by viral infections, but bacteria, parasites, and fungi can also cause it. Some cases improve without treatment, while others can cause death and require emergency antibiotic treatment. Seeking immediate medical care is crucial for preventing serious complications.

Market Scope

For more details on this report – Request for Sample

Market Dynamics: Drivers & Restraints

Rise in the prevalence of meningitis

The global meningitis diagnostic testing market is driven by rising global prevalence, demand for advanced diagnostics, point-of-care diagnostic services, and research and development investments for effective diagnosis and treatment, with the forecast period expected to be dominated by these factors.

For instance, according to a recent article published in NCBI,  The incidence of meningitis worldwide is estimated to be 20 cases per 100,000 people; that is, about 1.2 million; the incidence and causes vary across geographic regions.

Shortage of skilled professionals

Accurate diagnosis of meningitis is crucial for timely and effective treatment, as the condition can progress rapidly and result in severe complications or death. However, several challenges related to the shortage of skilled healthcare professionals, particularly in rural and underdeveloped areas, can restrict the usage and effectiveness of diagnostic tests. 

The lack of skilled professionals can lead to delays in diagnosis, which is critical for conditions like meningitis that progress rapidly. Delayed diagnosis can result in worse outcomes, including higher morbidity and mortality rates.

Segment Analysis

The global meningitis diagnostic testing market is segmented based on infection type, diagnosis type, end-user, and region.

The PCR assay  from the diagnosis type segment accounted for approximately 39.5% of the meningitis diagnostic testing  market share

The PCR assay from the diagnosis type segment accounted for approximately 39.5%. The PCR assay segment is expected to dominate during the forecast period owing to the factors like, the availability of RT-PCR platforms, which provide results in less than two hours, including multi-target and single-target detection tests. Technological advancements in PCR assays, which reduce turnaround times and promote precise diagnosis, are expected to further drive the segment's growth. The high sensitivity and precision of PCR tests are expected to further increase their adoption in meningitis testing.

For instance, in January 2024, QIAGEN announced that its QIAstat-Dx Meningitis/Encephalitis Panel, a qualitative multiplexed nucleic acid-based in vitro diagnostic test has received approval from the Health Sciences Authority Singapore (HSA).  The QIAstat-Dx system is designed for use in laboratories and employs cost-efficient, single-use cartridges with all reagents on board and built-in sample processing. Utilizing multiplex real-time PCR, it detects and differentiates between multiple pathogens.3

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors due to strategic initiatives and the presence of leading players. High adoption of advanced diagnostic devices, easy access to test kits, increased awareness about early diagnosis, and an increase in diagnostic centres are expected to fuel region expansion. Government initiatives to promote infectious disease diagnosis offer lucrative growth opportunities in the future.

Covid 19 Impact Analysis

The COVID-19 pandemic significantly impacted the meningitis diagnostics testing market, as many people struggled to get routine immunizations due to the unavailability of primary care or self-isolation requirements. For instance, in February 2022, a study in Clinical Epidemiology and Global Health reported a meningitis outbreak in the Democratic Republic of Congo, causing strain on healthcare systems and a high case fatality rate of 50%.

Market Segmentation

By Infection Type

• Bacterial
• Viral
• Fungal
• Others

By Diagnosis Type

• Latex Agglutination Tests
• PCR Assay
• Lateral Flow Assay
• ELISA Tests
• Culture Test
• Others

By End-User

• Hospitals
• Diagnostic Laboratories
• Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Thermo Fisher Scientific Inc, Seegene Inc., BioFire Diagnostics LLC (BioMérieux), Teco Diagnostics, ELITech Group, Transasia Bio-Medicals Ltd, Lepu Medical Technology Eurolyser Diagnostica, Gold Standard Diagnosticsa, Biorad laboratories Inc among others.

Key Developments

• On October 26, 2023, LumiraDx unveiled a groundbreaking development in the field of medical diagnostics—the launch of its cutting-edge meningitis NxGen MenB & Group C/G/Y Assay. This innovative molecular test represents a significant leap forward in point-of-care testing for meningitis B and other serogroups, promising a revolution in the timely diagnosis and treatment of this critical health condition.
• In July 2022, Abacus Diagnostica, a Uniogen company, launched a new rapid PCR test GenomEra assay kit (HSV-1/2, VZV + EV Assay Kit) in the European markets for the fast identification of viruses causing viral meningitis and encephalitis. This is a significant development in medical technology as it will allow for faster and more accurate diagnoses of these serious illnesses.

Why Purchase the Report?

• To visualize the global meningitis diagnostic testing market segmentation based on infection type, diagnosis type, end user, and region as well as understand key commercial assets and players.
• identify commercial opportunities by analyzing trends and co-development. 
• excel data sheet with numerous data points of the meningitis diagnostic testing market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global meningitis diagnostic testing market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies